Athenex

General Information
Business:

We are a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Our mission is to improve the lives of cancer patients by creating more effective, safer and tolerable treatments. We have generated our clinical product candidates through our Orascovery and Src Kinase Inhibition research platforms, which are based on our understanding of human absorption biology and novel approaches to inhibiting kinase activity, respectively.

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 437
Founded: 2003
Contact Information
Address 1001 Main Street, Suite 600, Buffalo, NY 14203, US
Phone Number (716) 427-2950
Web Address http://www.athenex.com
View Prospectus: Athenex
Financial Information
Market Cap $662.98mil
Revenues $20.5 mil (last 12 months)
Net Income $-118.1 mil (last 12 months)
IPO Profile
Symbol ATNX
Exchange NASDAQ
Shares (millions): 6.0
Price range $11.00 - $11.00
Est. $ Volume $66.0 mil
Manager / Joint Managers Credit Suisse/ Deutsche Bank Securities/ J.P. Morgan
CO-Managers ICBC International
Expected To Trade: 6/14/2017
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change